首页|罗哌卡因复合舒芬太尼硬膜外麻醉在初产妇阴道分娩镇痛中的应用

罗哌卡因复合舒芬太尼硬膜外麻醉在初产妇阴道分娩镇痛中的应用

扫码查看
目的 探讨罗哌卡因复合舒芬太尼硬膜外麻醉(EA)在初产妇阴道分娩(VD)镇痛中的应用效果。方法 选取 2019 年 7 月至 2023 年 6 月在永煤集团总医院进行VD的 80 例初产妇,以随机数字表法分成对照组(40 例)与研究组(40例),两组均给予EA,对照组应用罗哌卡因,研究组应用罗哌卡因复合舒芬太尼,比较两组麻醉指标、疼痛程度、产程、分娩结局、母婴结局。结果 研究组麻醉起效、完全阻滞用时短于对照组,麻醉持续时间更长,差异有统计学意义(P<0。05);两组麻醉10 min、1 h、2 h后数字评分法(NRS)评分低于麻醉前,且同时段研究组NRS评分低于对照组,差异有统计学意义(P<0。05);研究组第一、二、三产程用时短于对照组,差异有统计学意义(P<0。05);研究组中转剖宫产发生率(2。50%)低于对照组,差异有统计学意义(P<0。05);研究组不良母婴结局发生率(5。00%)低于对照组(22。50%),差异有统计学意义(P<0。05)。结论 罗哌卡因复合舒芬太尼EA应用于VD初产妇,能够改善麻醉指标,降低初产妇疼痛程度,缩短产程,减少中转剖宫产、不良母婴结局发生率。
Application of Ropivacaine Combined with Sufentanil Epidural Anesthesia in Pain Relief during Vaginal Delivery in Primiparas
Objective To explore the application effect of ropivacaine combined with sufentanil epidural anesthesia(EA)in pain relief during vaginal delivery(VD)in primiparas.Methods A total of 80 primiparas who underwent VD in Yongmei Group General Hospital from July 2019 to June 2023 were selected,and they were divided into the control group(40 cases)and the research group(40 cases)by the random number table method.Both groups were given EA,the control group used ropivacaine,and the research group used ropivacaine combined with sufentanil.The anesthesia indicators,pain degree,labor process,delivery outcome,and maternal and infant outcomes of the two groups were compared.Results The onset time and complete block time of the research group were shorter than those of the control group,and the duration of anesthesia was longer,with statistically significant differences(P<0.05).The Numeric Rating Scale(NRS)scores of the two groups 10 min,1 h,and 2 h after anesthesia were lower than before anesthesia,and the NRS scores of the research group at the same time were lower than those of the control group,with statistically significant differences(P<0.05).The first,second,and third stages of labor in the research group were shorter than those in the control group,with statistically significant differences(P<0.05).The rate of conversion to cesarean section in the research group(2.50%)was lower than that in the control group,with statistically significant differences(P<0.05).The rate of adverse maternal and infant outcomes in the research group(5.00%)was lower than that in the control group(22.50%),with statistically significant differences(P<0.05).Conclusion The application of ropivacaine combined with sufentanil EA in VD primiparas can improve anesthesia indicators,reduce the pain degree of primiparas,shorten the labor process,reduce the rate of conversion to cesarean section,and the occurrence rate of adverse maternal and infant outcomes.

vaginal deliveryprimiparasropivacainesufentanilepidural anesthesia

杨龙华、孔全立、刘楠楠、黄胜豪、李萌、徐庆华、廖雨涛

展开 >

永煤集团总医院 麻醉科,河南 商丘 476600

河南大学第一附属医院 麻醉科,河南 开封 475000

阴道分娩 初产妇 罗哌卡因 舒芬太尼 硬膜外麻醉

2024

临床研究
西安交通大学

临床研究

影响因子:0.234
ISSN:2096-1278
年,卷(期):2024.32(7)